Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges

Joseph J Cuthbert¹,², Pierpaolo Pellicori³, Andrew L Clark²

¹Centre for Clinical Sciences, Hull York Medical School, Kingston Upon Hull, East Riding of Yorkshire, UK; ²Department of Cardiology, Hull University Teaching Hospital Trust, Kingston Upon Hull, East Riding of Yorkshire, UK; ³Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK

Correspondence: Joseph J Cuthbert, Department of Cardiorespiratory Medicine, Centre for Clinical Sciences, Hull York Medical School, Hull and East Yorkshire Medical Research and Teaching Centre, Castle Hill Hospital, Cottingham, Kingston Upon Hull, HU16 5JQ, UK, Tel +44 1482 461776, Fax +44 1482 461779, Email joe.cuthbert@hyms.ac.uk

Abstract: Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are common causes of breathlessness which frequently co-exist; one potentially exacerbating the other. Distinguishing between the two can be challenging due to their similar symptomatology and overlapping risk factors, but a timely and correct diagnosis is potentially lifesaving. Modern treatment for HF can substantially improve symptoms and prognosis for many patients and may have beneficial effects for patients with COPD. Conversely, while many inhaled treatments for COPD can improve symptoms and reduce exacerbations, there is conflicting evidence regarding the safety of some inhaled treatments for COPD in patients with HF. Here we explore the overlap between HF and COPD, examine the effect of one condition on the other, and address the challenges of managing patients with both conditions.

Keywords: chronic obstructive pulmonary disease, heart failure, management, outcomes, comorbidities

Introduction

Breathlessness on exertion is an enormously common presenting complaint, affecting between 10% and 20% of the adult population,¹³ and up to two-thirds of those aged over 60 years.⁴–⁶ Distinguishing between heart failure (HF), chronic obstructive pulmonary disease (COPD), both, or neither can be challenging due to the large overlap in symptoms, clinical signs, co-morbidities and risk factors – especially smoking history. Furthermore, the pre-existing diagnosis of one condition may obscure the diagnosis of the other, as clinicians might fail to consider additional causes of breathlessness.⁷

Distinguishing between the two – and identifying one despite the presence of the other – is essential for controlling symptoms and improving prognosis. Medical management of HF due to a reduced ejection fraction (HFrEF) can almost double life expectancy.⁸ There is little data to suggest inhaled treatments for COPD have a prognostic benefit;⁹–¹² the recent ETHOS and IMPACT trials of inhaled therapies for patients with COPD have suggested a reduced mortality for patients treated with triple therapy (inhaled glucocorticoid, long-acting antimuscarinic, and long acting beta-agonist) compared to dual therapy but event rates were low and neither trial was powered to detect a mortality difference.¹³,¹⁴ Inhaled therapies can substantially improve symptoms and reduce the risk of exacerbations for patients with COPD,¹⁵ but may have harmful effects in patients with HF.¹⁶–¹⁸ Conversely, loop diuretics can greatly improve symptoms of congestion in patients with HF,¹⁹ but would have minimal impact on the symptoms of patients with airway obstruction.

Prevalence of COPD in Patients with HF

The prevalence of COPD in patients with HF varies depending on the population and the definition used (Figure 1). Using a non-standard definition (either self-reported by the patient or based on physician assessment, COPD treatment, or from review of the medical notes) the prevalence ranges between 10 and 25% (Table 1).²⁰–²⁸ Using spirometry to define
The presence of COPD, the prevalence is higher and ranges between 25 and 50% (Table 2).

The reasons for this discrepancy is unclear, but it may be due to undiagnosed COPD in patients with HF: the patient is breathless and the clinician has objective evidence of cardiac dysfunction (raised natriuretic peptide levels and/or reduced left ventricular ejection fraction (LVEF)), another potential cause of the symptoms may go overlooked. Alternatively, abnormal findings on spirometry may be due to HF rather COPD.

Pulmonary congestion may compress small airways causing an obstructive clinical picture on spirometry that resolves with adequate treatments, particularly diuresis.

In one small study (N = 272), half of patients with HF and obstructive spirometry at baseline had normal spirometry after 6 months of treatment with loop diuretics, angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), beta-blocker, and mineralocorticoid receptor antagonist. However, while abnormal spirometry is common amongst patients admitted with heart failure, a restrictive pattern is nearly three times more common than an obstructive, or mixed, pattern.

COPD (among other causes of breathlessness) should be considered in all patients with HF who are breathless despite having no signs of congestion, although the prognostic benefits of diagnosing and treating COPD in patients with established HF remain questionable. Of those studies which used non-standardised definitions of COPD, some suggest that the co-diagnosis of COPD and HF is associated with a 20–30% greater risk of death compared to HF alone,

while others suggest no, or only weak, associations between the presence of COPD and greater risk of adverse outcome.

In the two largest cohorts which diagnosed COPD via spirometry (N~11,000 combined), the presence of COPD in patients with HF was not associated with a greater risk of mortality but was associated with an increased risk of readmission in the month following discharge following an admission with HF.

Prevalence of HF in Patients with COPD

Although there is a large overlap in risk factors for HF and COPD, COPD may be an independent risk factor for incident HF: exacerbations are associated with an increased risk of myocardial infarction (among other cardiovascular events) which is the most common cause of HeFREF. Amongst those with COPD, the prevalence of HF based on the findings from examination,
investigations, or information in the medical record ranges between from 5% to 20% (Figure 2). However, up to 50% of patients with COPD have high serum natriuretic peptide concentrations (a key diagnostic criterion for HF suggestive of underlying cardiac dysfunction).

The presence of HF in patients with COPD is consistently associated with an increased risk of morbidity and mortality compared to COPD alone. Patients with high natriuretic peptide concentrations may have significant underlying cardiac dysfunction regardless of whether they fit the current diagnostic criteria for HF, and the presence of raised NP concentrations is associated with a higher mortality in patients with COPD.

Medical treatment for HFrEF is associated with a 50–60% reduction in the risk of HF hospitalisation or cardiovascular mortality. Thus, identifying and treating HF in a patient with COPD may have an enormous beneficial effect on prognosis.

**Distinguishing HF from COPD and Vice Versa**

**History & Clinical Examination**

An accurate history alone is unlikely to be able to distinguish HF from COPD but may give some clues. Patients with either condition predominantly present with progressive breathlessness, which may be interpreted as a sign of old age, or

---

**Table 1: Studies of COPD Prevalence in Patients with HF Not Using Spirometry**

<table>
<thead>
<tr>
<th>Study</th>
<th>Cohort</th>
<th>HF Phenotype</th>
<th>Definition of COPD</th>
<th>Prevalence of COPD</th>
<th>Beta-Blocker (COPD vs No COPD)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Blois (2010)</td>
<td>N=4132 Norwegian HF registry</td>
<td>&gt;90% HeFREF CHF</td>
<td>ICD 9</td>
<td>20%</td>
<td>74% vs 84%</td>
<td>COPD associated with increased risk of all-cause mortality (HR=1.19; p=0.03)</td>
</tr>
<tr>
<td>Mentz (2012)</td>
<td>N=4133 EVEREST trial cohort</td>
<td>HeFREF AHF</td>
<td>Medical record</td>
<td>10%</td>
<td>63% vs 71%</td>
<td>COPD not associated with mortality or hospitalisation after adjustment for other variables</td>
</tr>
<tr>
<td>Mentz (2012)</td>
<td>N=20118 OPTIMIZE-HF registry</td>
<td>HeFREF AHF</td>
<td>Investigator reported</td>
<td>25%</td>
<td>66% vs 75%</td>
<td>COPD not associated with in-hospital or post discharge mortality after adjustment for other variables</td>
</tr>
<tr>
<td>Tavazzi (2013)</td>
<td>N=6505 SHIFT trial cohort</td>
<td>HeFREF CHF</td>
<td>Medical record</td>
<td>11%</td>
<td>69% vs 92%</td>
<td>COPD associated with an increased risk of HF hospitalisation or CV mortality (HR 1.22; p=0.006)</td>
</tr>
<tr>
<td>Canepa (2018)</td>
<td>N=16329 ESC HF long-term registry</td>
<td>73% HeFREF 57% CHF</td>
<td>Investigator reported</td>
<td>19% in AHF 14% in CHF</td>
<td>72% vs 85%</td>
<td>COPD associated with an increased risk of all-cause hospitalisations but not associated with mortality after adjustment for other variables</td>
</tr>
<tr>
<td>Canepa (2017)</td>
<td>N=6975 GISSI-HF trial cohort</td>
<td>~90% HeFREF CHF</td>
<td>Investigator reported</td>
<td>22%</td>
<td>44% vs 71%</td>
<td>COPD associated with an increased risk of all-cause mortality (HR 1.28; p&lt;0.001) and CV hospitalisation (HR 1.23; p&lt;0.001)</td>
</tr>
<tr>
<td>Ehteshami-Afshar (2021)</td>
<td>N=8399 PARADIGM-HF cohort</td>
<td>HeFREF CHF</td>
<td>Investigator reported</td>
<td>13%</td>
<td>87% vs 94%</td>
<td>COPD associated with an increased risk of CV hospitalisations but not mortality</td>
</tr>
<tr>
<td>Dewan (2021)</td>
<td>N=4744 DAPA-HF cohort</td>
<td>HeFREF CHF</td>
<td>Investigator reported</td>
<td>12%</td>
<td>92% vs 97%</td>
<td>COPD associated with an increased risk of worsening HF or CV mortality (HR = 1.44; P&lt;0.001)</td>
</tr>
</tbody>
</table>

---

The International Journal of General Medicine publication date is 2022:15.

https://doi.org/10.2147/IJGM.S295467

Dovepress

Cuthbert et al

Powered by TCPDF (www.tcpdf.org)
fatigue – another symptom common in HF. Obesity might impair respiratory mechanics, but carrying a substantial excess of body fat might also cause exertional breathlessness. Ankle swelling is a non-specific symptom of cardiac dysfunction that may go unrecognised by patients and their clinicians. However, advanced lung disease can cause raised pulmonary arterial pressures – type III pulmonary hypertension or cor pulmonale – which itself can cause peripheral oedema and ankle swelling.

Daytime cough is a common symptom of COPD, particularly in chronic smokers, but is also seen, less commonly, in patients with HF. Cough in patients with HF is most likely to be due to pulmonary congestion, and rarely due to treatment with an ACEI. Nocturnal cough and breathlessness (paroxysmal nocturnal dyspnoea) due to lying flat is an indication of worsening pulmonary congestion in patients with HF. Nocturnal symptoms are claimed to be uncommon in patients with COPD, but up to 20% of patients with severe COPD may suffer from chest tightness, breathlessness, or cough which are worse at night. Sputum production is a common feature of COPD but rare in patients with HF (except in the case of frank pulmonary oedema in which patients may produce pink, frothy sputum). Symptoms of advanced disease, such as weight loss and frailty, are common to both conditions.

Concurrent medications may also offer useful clues: chronic use of medications such as loop diuretics or digoxin might indicate underlying cardiac dysfunction and is associated with a greater risk of cardiovascular events, even in the absence of a heart failure diagnosis.

<table>
<thead>
<tr>
<th>Study</th>
<th>Cohort</th>
<th>HF Phenotype</th>
<th>Definition of COPD</th>
<th>Prevalence of COPD</th>
<th>Beta-Blocker (COPD vs No COPD)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iversen (2010)</td>
<td>N=527 ECHOS trial cohort</td>
<td>58% HeFREF CHF</td>
<td>Post-bronchodilator FEV₁; FEV₁:FVC GOLD criteria</td>
<td>35%</td>
<td>17% vs 32%</td>
<td>Lower FEV₁ associated with an increased risk of mortality but lower FEV₁:FVC was not regardless of HF phenotype</td>
</tr>
<tr>
<td>Brenner (2013)</td>
<td>N=619 Sub-group of Interdisciplinary Network HF Study</td>
<td>HeFREF AHF</td>
<td>Post-bronchodilator FEV₁; FEV₁:FVC GOLD criteria</td>
<td>23%</td>
<td>88% vs 92%</td>
<td>COPD associated with increased risk of all-cause mortality (HR=1.64; P=0.04)</td>
</tr>
<tr>
<td>Yoshihisa (2014)</td>
<td>N=378 Hospitalised with HF</td>
<td>Mixed cohort AHF</td>
<td>No bronchodilator FEV₁; FEV₁:FVC</td>
<td>28%</td>
<td>58% vs 70%</td>
<td>Mild COPD not associated with outcomes but moderate COPD (FEV₁; FVC &lt;0.7 and FEV₁ 50–80% of predicted) associated with increased risk of all-cause mortality</td>
</tr>
<tr>
<td>Jacob (2016)</td>
<td>N=8099 EAHFE cohort – patients presenting to ED with ADHF</td>
<td>Mixed cohort AHF</td>
<td>No bronchodilator FEV₁; FEV₁:FVC</td>
<td>26%</td>
<td>30% vs 45%</td>
<td>COPD associated with an increased risk of re-hospitalisation but not mortality.</td>
</tr>
<tr>
<td>Plesner (2017)</td>
<td>N=573 Stable out-patients with HF</td>
<td>HeFREF CHF</td>
<td>No bronchodilator FEV₁; FEV₁:FVC</td>
<td>39%</td>
<td>75% vs 78%</td>
<td>COPD associated with an increased risk of all-cause mortality (HR = 2.07; P&lt;0.01)</td>
</tr>
<tr>
<td>Cuthbert (2019)</td>
<td>N=4986 Stable outpatients with HF</td>
<td>83% HeFREF CHF</td>
<td>No bronchodilator FEV₁; FEV₁:FVC</td>
<td>50%</td>
<td>55% vs 63%</td>
<td>COPD not associated with HF hospitalisation or all-cause mortality after multivariable adjustment</td>
</tr>
</tbody>
</table>
Clinical signs of bronchoconstriction (such as wheeze) or congestion (such as a raised jugular venous pulse) are often difficult to elicit, lack specificity, and may only be present with severe disease. Further investigation is usually essential.

**Investigations**

Unless there is pulmonary oedema, the chest X-ray (CXR) findings listed in textbooks in patients with either HF or COPD are often non-specific and a normal CXR excludes neither condition. The real value of a CXR in a patient presenting with breathlessness and/or cough is to exclude other possible pathologies such as pneumonia, lung cancer, or pulmonary fibrosis. Conversely, a normal electrocardiogram (ECG) has a negative predictive value of 98% for the presence of significant cardiac dysfunction, but would not rule out COPD. The finding of x-ray changes consistent with COPD in a patient with HF, or ECG changes in a patient with COPD should not be ignored and prompt investigation for the other pathology.

Measuring serum natriuretic peptide concentration in patients with breathlessness and suspected HF is recommended by international specialist guidelines. As with a normal ECG, normal natriuretic peptide concentrations make a diagnosis of HF highly unlikely. Very high concentrations, on the other hand, are associated with a poor prognosis regardless of underlying conditions or left ventricular systolic function. However, there are multiple causes of raised serum NP concentration, including COPD, although concentrations tend to be lower than in patients with left ventricular systolic dysfunction, even during an exacerbation. The underlying cause of raised NP concentrations in patients presenting with breathlessness is rarely clear from history, examination, and blood tests alone: in a patient with COPD, it may indicate the presence of pulmonary hypertension due to severe lung disease, the presence of left ventricular systolic dysfunction, or atrial fibrillation. Thus, when NPs are abnormal, assessment of cardiac structure and function is required, most commonly via transthoracic echocardiography (TTE).

**Echocardiography and Spirometry**

Approximately half of patients with the superficial “heart failure syndrome” – breathlessness, signs of congestion, and raised NP concentrations – will have a left ventricular ejection fraction (LVEF) within the normal range (>50%), variously termed HF with a preserved or normal ejection fraction (HFpEF/HFnEF).
Echocardiography can also give an estimate of pulmonary artery systolic pressure using Doppler imaging, thereby indicating the presence of pulmonary hypertension but offers only limited information on the aetiology of high pulmonary pressures. Echocardiography may also raise the suspicion of amyloidosis or other rarer cardiomyopathies which require further investigation.

However, the main purpose of a TTE in patients with breathlessness and raised NP concentrations is to identify or exclude HFrEF or severe valve disease, both of which can be treated with profound beneficial effects on symptoms and prognosis. While low LVEF on TTE makes the management plan easier, it does not exclude concurrent COPD. Spirometry is the standard test for diagnosing COPD. If the ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) is below 0.7 despite the administration of bronchodilator, there is obstructive pulmonary disease. However, just as with LVEF measured on echocardiography, spirometry can be misleading – as many as 1 in 4 patients with an FEV1/FVC ratio <0.7 on one day may have a normal ratio on a different day in whom a differential diagnosis of asthma ought to be considered. Many patients with normal spirometry have symptoms, signs, radiographic evidence of, and frequent exacerbations consistent with COPD. Furthermore, many patients with heart failure also have obstructive spirometry which improves with diuresis.

Both conditions have “quick-fix” symptomatic treatments – loop diuretics in the case of HF; short-acting beta-agonists in the case of COPD. Given the inherent difficulties with establishing a diagnosis, a trial of treatment with either (but not both together) may be the best way to clarify the diagnosis or, in the case of concurrent HF and COPD, clarify which condition has the greatest symptomatic impact. However, symptomatic improvement is not a valid excuse to not investigate for other diagnoses, should the clinical suspicion remain.

Patients can have as many diseases as they damn well please.


Effect of HF Treatments on Patients with COPD
Renin Angiotensin Aldosterone System Inhibitors

Drugs that inhibit the renin angiotensin aldosterone system (RAAS) – angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), and angiotensin receptor neprilysin inhibitors (ARNI) – are the cornerstone of medical management of HFrEF, but there is increasing evidence that they may provide prognostic benefit for some patients with HF and a higher LVEF.

RAAS activation may also be implicated in the pathogenesis of COPD. In vivo and in vitro studies have found that angiotensin II (AngII) stimulates the release of inflammatory cytokines such as interleukin, tumour necrosis factor α, and monocyte chemotactic protein 1. The latter activates tissue mast cells in response to alveolar hypoxia, thus potentially driving the local and systemic inflammatory response in patients with COPD. AngII also increases inflammatory cell migration, epithelial cell apoptosis, and fibroblast activity in the lung parenchyma. It enhances bronchoconstriction driven by muscarinic receptor activation, and drives the cytokine mediated immune response to lung injury. In human tissue, expression of angiotensin receptor 1 (AT1) is higher in fibrosed lung of patients with COPD compared to those with no pulmonary disease. AngII may thus contribute to the development and progression of lung inflammation and fibrosis associated with COPD and losartan – an AT1 blocker can inhibit some aspects of lung injury.

ACEIs or ARBs can improve histological appearances, lung compliance, exercise capacity, and reduce lung fibrosis in animal models of pulmonary disease. Retrospective data suggest that patients with COPD who either take an ACEI or ARB have slower decline in lung function, and slower progression of emphysematous changes on computed tomography than those that do not. However, trials of the effect of ACEI or ARB on pulmonary function or exercise capacity in patients with COPD have produced inconsistent results. Of note, in a double-blind randomised controlled trial (RCT) (N = 80), treatment with enalapril for 10 weeks, alongside a cardiopulmonary exercise rehabilitation programme, was associated with improved peak work rate in patients with at least moderate COPD compared to those undergoing the rehabilitation programme alone. No prospective randomised clinical trial has investigated the effect of RAAS inhibitors on morbidity and mortality in patients with COPD and no cardiovascular indication for treatment.
The use of ACEI or ARB tends to be lower amongst patients with HF and COPD compared to those with HF alone. The reasons for this are unclear but may be due to clinicians overlooking other causes of breathlessness in patients with an established diagnosis of COPD and not treating HF effectively as a result. The benefits of medications that inhibit the RAAS in patients with HFrEF are clear and, in the case of ACEI or ARB, may also benefit patients with COPD (Figure 3).

**Beta-Blockers**

Initially thought to be detrimental in patients with HF, beta-blockers are now considered first-line treatment with perhaps the greatest prognostic benefit for patients with HFrEF. There is often great unease regarding the safety of beta-blocker in patients with COPD.

Almost all HF registry and trial data report that a lower proportion of patients with HF and COPD are treated with beta-blockers compared to patients with HF but without COPD. Anxiety about beta-blocker induced bronchoconstriction and concerns that beta-blockers might also reduce the efficacy of inhaled beta-agonist treatment have some evidence to support them. In those with obstructive lung disease, treatment with beta-blockers is associated with a fall in FEV\(_1\) and an increase in wheeze; non-selective beta-blockers (such as carvedilol which antagonises β1, β2, and α1 adrenoceptors) reduce FEV\(_1\) by ~100 mL more than do cardio-selective beta-blockers (such as metoprolol or bisoprolol which antagonises β1 only). Some observational data suggest that the rate of hospitalisation with COPD is greater within 60 days of starting a non-selective beta-blocker in patients with HFrEF and concurrent COPD compared to HF alone, and that the risk of death in patients with COPD on long-term oxygen therapy is higher among those taking beta-blockers.

COPD, like HF, is associated with adrenergic activation and high concentrations of circulating inflammatory cytokines. Activation of one system increases activation of the other, particularly in the context of an exacerbation. Cardiovascular death is common amongst patients with COPD, and use of beta-blockers is

---

**Figure 3** Proposed interactions of medical therapy for HF and COPD.  
**Note:** Data from References 76–93; 98–100,102–105,120–125, 136–161.  
**Abbreviations:** ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; SGLT2I, sodium-glucose co-transporter 2 inhibitor; ICS, inhaled corticosteroid; QoL, quality of life; AngII, angiotensin II; CO\(_2\), carbon dioxide; COPD, chronic obstructive pulmonary disease.
associated with a reduced risk of mortality amongst patients with COPD in some observational cohorts.\textsuperscript{106,107} However, the only RCT to assess beta-blocker use in patients with moderate or severe COPD and no other cardiovascular indication (N = 532) was stopped prematurely because of futility and safety concern: patients randomised to metoprolol had a 91\% greater risk of developing a severe COPD exacerbation compared to those assigned to placebo.\textsuperscript{108} Further trials are ongoing.\textsuperscript{109,110}

In practice, beta-blockers are well tolerated in the majority of patients with COPD, even during exacerbations,\textsuperscript{111,112} but are only tolerated in half of patients with asthma.\textsuperscript{113} While beta-blockers may be associated with worse COPD-related outcomes in those with severe COPD, their benefit in patients with HFrEF is profound and well established and widely recommended, regardless of a COPD diagnosis.\textsuperscript{50} In clinical practice, for patients with HF and COPD, cardio selective beta-blockers should be preferred and started at a low dose, closely monitoring for early signs of airway obstruction.

**Sodium Glucose Co-Transporter-2 Inhibitors**

Sodium glucose co-transporter 2 inhibitors (SGLT2i) were developed as anti-hyperglycaemic medications. The sodium glucose co-transporter 2 is responsible for reabsorption of sodium and glucose in the proximal convoluted tubule, thus inhibition of the transporter induces glycosuria and natriuresis.\textsuperscript{114} Initially investigated in patients with diabetes, Phase III studies found a reduction in HF hospitalisation regardless of the presence of HF at baseline.\textsuperscript{115,116} Subsequent trials confirmed prognostically beneficial effects of SGLT2i in patients with heart failure regardless of LVEF or a diagnosis of type II diabetes.\textsuperscript{117,118}

A meta-analysis of 9 large RCTs of SGLT2i in various patient populations suggested that treatment with SGLT2i may reduce the risk of hospital admission with COPD exacerbation compared to placebo (hazard ratio 0.77 (95\% confidence interval 0.61–0.97; P = 0.03)).\textsuperscript{119} The underlying mechanisms of benefits of SGLT2i are much debated but are likely to be due, mostly, to the osmotic diuretic effect of glycosuria.\textsuperscript{120} Thus, in those with HF, SGLT2i might decrease pulmonary congestion,\textsuperscript{121} and theoretically improve lung function, reducing the risk of infective COPD exacerbations (Figure 3). Overall, in clinical trials, SGLT2i has been well tolerated in different populations and there is no indication that patients with COPD are more likely to be intolerant of the treatment.

**Diuretics**

Loop diuretics are vital for controlling symptoms of venous congestion in HF.\textsuperscript{50} Venous congestion is also a feature of cor pulmonale, and thus loop diuretics are prescribed to some patients with COPD with no diagnosis of left ventricular dysfunction. Pulmonary congestion may cause worsening of lung function and obstructive physiology on spirometry.\textsuperscript{36} Titration of HF medications (including diuretics) to reduce pulmonary artery pressure is associated with a lower rate of hospitalisation due to respiratory infection.\textsuperscript{122} A large observational analysis of patients in primary care in the UK suggests that early diagnosis and better management of HF, including a more appropriate use of diuretics, are associated with a lower risk of COPD exacerbation (Figure 3).\textsuperscript{123}

There are other potential mechanisms of benefit with loop diuretics: air hunger (the sensation of inadequate inspiration, reduced by taking deep breaths) is a common feature of respiratory disease, most likely due to stimulation of stretch receptors (slowly adapting pulmonary stretch receptors) in the lung parenchyma.\textsuperscript{124} Increased intracellular sodium concentration may increase activation of these stretch receptors,\textsuperscript{125,126} and furosemide (which inhibits Na$^{+}$/K$^{+}$/2Cl$^{-}$ co-transporters increasing sodium concentrations in lung parenchyma) is associated with increased activity of the stretch receptors in animal models.\textsuperscript{127} Although nebulised furosemide reduces the sensation of air hunger in healthy volunteers,\textsuperscript{128} it has no effect on breathlessness in patients with lung disease.\textsuperscript{129} There are no trial data on the symptomatic or prognostic effect of loop diuretics in patients with COPD.

**Management of COPD in Patients with HF**

**Inhaled Treatments**

Short- and long-acting beta-agonists improve respiratory function and symptoms for patients with COPD and are the first-line treatment for COPD.\textsuperscript{56} Before the discovery of the benefits of RAAS and adrenergic system antagonism in the
1980s and ‘90s, small studies in patients with HF found that β-2 selective agonists increased LVEF and cardiac output.\textsuperscript{130,131}

However, the partial beta agonist xamoterol caused a three-fold higher mortality after 3 months of treatment in patients with HFrEF compared to placebo.\textsuperscript{132} The CIBIS I trial found that a beta-receptor antagonist, bisoprolol, was associated with improved symptoms and quality of life with a signal of improved outcomes.\textsuperscript{133} As more trials demonstrated the beneficial effects of beta-blockers, enthusiasm for investigating beta-agonists for the treatment of HF evaporated. Indeed, some observational data suggests that inhaled beta-agonists are associated with an increased risk of HF hospitalisation or death in patients with HFrEF.\textsuperscript{13,14}

Tiotropium and ipratropium inhalers are often used in combination with long-acting beta-agonists in patients with COPD who remain breathless despite frequent use of a short-acting treatment.\textsuperscript{56} Both tiotropium and ipratropium are associated with improved symptoms and a reduced risk of COPD exacerbation.\textsuperscript{134} However, both are also associated with an increased risk of cardiovascular and all-cause mortality in meta-analyses,\textsuperscript{18,135} possibly due to pro-ischaemic or pro-arrhythmic effects (Figure 3).\textsuperscript{136,137}

While inhaled corticosteroids (ICS) are as effective as long-acting inhaled beta-agonists for improving symptoms and reducing the risk of exacerbation in patients with COPD,\textsuperscript{138} there is little evidence of additional benefit on top treatment with long-acting beta-agonists or antimuscarinic inhalers.\textsuperscript{139,140} Guidelines recommend ICS use is reserved for patients with severe disease or frequent exacerbations,\textsuperscript{56} yet they remain one of the most commonly prescribed inhaled therapies for patients with COPD.\textsuperscript{141}

ICS are associated with increased risk of several conditions such as osteoporosis, cataracts, diabetes, and perhaps most relevant to patients with HF or COPD: pneumonia. Respiratory infection is a common reason for hospital admission and death amongst patients with HF.\textsuperscript{142,143} Use of ICS may expose the patient with COPD and HF to a higher risk of adverse outcome with little benefit.

However, the associations between inhaled therapies and adverse cardiovascular outcomes are far from certain. For example, in a meta-analysis of 23 RCTs involving >20,000 patients there was no difference in the cardiovascular adverse event rate between long-acting beta-agonist (LABA) plus long-acting muscarinic antagonists (LAMA) combinations versus LAMA alone.\textsuperscript{144} Furthermore, the association between tiotropium use and increased mortality in meta-analyses was confined to those taking the soft mist inhaler only\textsuperscript{18} and was not reproduced in a large-scale RCT comparing mortality in patients randomised to soft mist or dry powder preparations.\textsuperscript{145}

Moreover, there are some data from RCTs suggesting that the addition of ICS to combined LAMA/LABA therapy may be associated with reduced cardiovascular mortality compared to LAMA/LABA therapy alone.\textsuperscript{13,14} COPD is associated with increased platelet activation,\textsuperscript{146} potentially increasing the risk of thrombotic cardiovascular events. Thus, ICS may reduce the risk of ischaemic heart disease by dampening systemic inflammation (Figure 3). However, the only RCT which has addressed this specific question – the SUMMIT trial – showed no mortality benefit with the addition of ICS.\textsuperscript{12}

Ultimately, the data regarding the safety of inhaled treatments for COPD in patients with HF are conflicting. If they offer symptomatic benefit, short- or long-acting beta agonists or muscarinic antagonists should not be withheld based on concerns regarding detrimental cardiovascular effects, most of which come from confounded observational data. However, de-prescribing inhaled therapy may be safe for some patients with COPD,\textsuperscript{147,148} and could be considered for some patients, particularly those with HF, if only for the sake of reducing treatment burden.

**Oral Treatments and Home Oxygen**

Oral steroids are a common treatment for a COPD exacerbation but rarely used as a long-term treatment. Despite historical concerns that long-term steroid treatment may increase salt and water retention, a particular problem in the context of co-existing HF, there are few data to back this up.\textsuperscript{149} In fact, short course steroid treatment can induce a profound diuresis in patients with HF and severe venous congestion who are not responding to conventional diuretic therapy,\textsuperscript{150} and may be associated with better outcomes amongst patients hospitalised with HF.\textsuperscript{151} There are no prospective trials of long-term oral steroids in patients with HF and the significant side-effect profile which may override any positive effects in patients with either COPD or HF.
Oral theophylline and mucolytics may be used in patients with severe COPD, but data on their use in patients with HF are limited. In a small study of euvoalaemic patients with HF and central sleep apnoea, a 5-day course of theophylline reduced the number of apnoic and hypopnoeic episodes and was well tolerated. However, theophylline metabolism may be reduced in patients with HF, potentially increasing the risks of adverse effects of the medication including arrhythmia.

Similarly, home oxygen is often prescribed to patients with end-stage COPD, and may improve outcomes for those with severe hypoxaemia. In the only RCT of home oxygen therapy for patients with severe HF, there was no difference in quality of life or measures of breathlessness after 6 months of treatment in patients randomised to oxygen compared to those receiving medical therapy alone.

**Summary**

Heart failure and COPD share common risk factors and pathophysiological mechanisms; thus, it is no surprise they frequently co-exist. A diagnosis of HF in a patient with COPD has a profound adverse effect on prognosis, but the additional diagnosis of COPD in a patient with HF seems to have little impact. Distinguishing one from the other is an enormous clinical challenge, even using “gold-standard” diagnostic tests but timely identification and treatment of the underlying disease process has a large impact on symptoms, quality of life and, in the case of HFrEF, long-term outcomes. Once a diagnosis of HFrEF has been established, early treatment with optimal medical therapy is essential. Caution is advised with beta-blockers, but the co-existence of COPD should not be a reason to withhold treatment: if there are concerns with bronchoconstriction with non-selective beta-blockers such as carvedilol switching to a cardio-selective beta-blocker such as bisoprolol may help. Bear in mind that most treatments for HFrEF, including loop diuretics, may also have favourable aspects on COPD in patients with both diagnoses. There are conflicting data regarding whether treatments for COPD are harmful to patients with HF: in selected cases, de-escalation of inhaled therapies should be considered in patients with co-existing COPD and HF. Establishing an accurate diagnosis and getting the balance of long-term treatments right are difficult but essential to improve management of both conditions.

**Acknowledgments**

Dr. Pellicori has received a research grant (Scotland Grant) from Heart Research UK (RG2676/18/21). The authors would like to thank Dr Michael Crooks of the Respiratory Research Group at the Hull York Medical School for his advice while drafting the manuscript.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Dovepress


https://doi.org/10.2147/TJCTOP.S195467

Dovepress

International Journal of General Medicine 2022:15
Dovepress


